Background Primaquine is the only available drug that clears mature Plasmodium falciparum gametocytes in infected human hosts, thereby preventing transmission of malaria to mosquitoes. However, concerns about dose-dependent haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) defi ciencies have limited its use. We assessed the dose-response association of single-dose primaquine for gametocyte clearance and for safety in P falciparum malaria.
Introduction
Eff ective drug therapy is a key component of malaria control and elimination strategies to reduce both morbidity from the disease and onward transmission to mosquitoes. 1 Artemisinin combination therapy (ACT), the fi rst-line treatment in sub-Saharan Africa, achieves excellent cure rates for Plasmodium falciparum through rapid clearance of the asexual stages of the parasite. As a consequence, ACT reduces the production of malaria transmission stages-gametocytes-and thereby restricts transmission potential. 2 However, onward malaria transmission is not completely prevented because of the inadequate eff ect of artemisinins and their partner drugs against mature gametocytes. If mature gametocytes are present before treatment, they persist after ACT, often at concentrations below the threshold for detection by conventional microscopy, 3 and can allow onward malaria transmission for up to 14 days after treatment. [3] [4] [5] [6] Primaquine, an 8-aminoquinoline, is the only available drug with established activity against mature gametocytes. It clears circulating gametocytes that persist after ACT, thereby reducing the duration of gametocyte carriage, [7] [8] [9] [10] [11] [12] and renders most patients free of gametocytes by day 14 after initiation of ACT-primaquine treatment. [7] [8] [9] 12 Primaquine reduces the transmission of malaria to mosquitoes-an eff ect that might precede the clearance of gametocytes. 13, 14 The transmission-blocking properties of primaquine have been reviewed in detail. 15 WHO has recommended one dose of primaquine in addition to ACTs for use in two scenarios: for malaria elimination programmes, and to stop the spread of emerging artemisinin resistance. 16 Primaquine is recommended for use in fi rst-line antimalarial treatment in many countries. 17 Despite these recommendations, primaquine is often not used because of concerns about its haemolytic eff ect in people with glucose-6-phosphate dehydrogenase (G6PD) defi ciency. Primaquine-induced haemolysis can occur after one dose of the drug 18 and is dose dependent. 19 Because doses of primaquine lower than the WHOrecommended dose can be equally effi cacious at clearance of P falciparum gametocytes, 15 dose optimisation for ACT-primaquine is needed.
No formal randomised controlled trials have been done to characterise the dose-response relation of primaquine for P falciparum gametocyte clearance. We aimed to assess the effi cacy of reduced doses of primaquine for non-inferiority to the WHO reference dose of 0•75 mg primaquine base per kg that has proven effi cacy, 7, 20 and to assess for superiority of the safety of reduced doses compared with placebo, in people with normal G6PD enzyme function.
Methods

Study design and participants
The study was a randomised, double-blind, placebocontrolled trial with four parallel groups. The study protocol has been described in detail elsewhere. 21 Briefl y, we undertook the study at Walukuba Health Centre IV in Jinja district, eastern Uganda, between December, 2011, and March, 2013. In this region, malaria transmission is perennial with seasonal peaks in intensity. An entomological inoculation rate of seven infectious bites per person per year was estimated in 2001. 22 Eligible participants were children aged 1-10 years attending the health centre with fever or history of fever in the past 24 h, P falciparum monoinfection with a parasite density lower than 500 000 per μL, and normal G6PD enzyme function based on a fl uorescence spot test (R&D Diagnostics, Aghia Paraskevi, Greece). Exclusion criteria were evidence of severe illness or danger signs, haemoglobin concentration less than 80 g/L, known allergy to the study drugs, antimalarials taken within the past 2 days, primaquine taken within the past 4 weeks, and blood transfusion within the past 90 days. Written informed consent was provided by parents or guardians and, in addition, assent was provided by children older than 8 years of age.
Ethics approval for the trial protocol and informed consent forms were provided by the Makerere University School of Medicine research ethics committee (protocol 2011-210), the Uganda National Council of Science and Technology (protocol HS1056), and the London School of Hygiene and Tropical Medicine research ethics committee (protocol 5987). The Ugandan National Drug Authority approved importation of the study drug. The trial data safety monitoring board and trial advisory committee were convened before the start of the trial and met at predetermined stages of the study. Con sultations with local community stakeholders in Walukuba were held before, during, and after trial completion.
Randomisation and masking
We randomly assigned eligible participants to one of four dose groups. In each group, we gave participants artemether-lumefantrine twice daily on days 0-2 and, with the fi fth dose of the drug, one dose of either placebo or primaquine (0•1 mg/kg, 0•4 mg/kg, or 0•75 mg/kg). A statistician at the London School of Hygiene and Tropical Medicine (ELW) computer-generated four-digit treatment assignment codes and allocated these to random dose groups in block sizes of 16. To achieve treatment concealment, we added masking syrup to all treatment groups, which disguised the colour and taste of the study drug. Because G6PD defi ciency is an X chromosomelinked disorder, we stratifi ed random isation by sex. Sequential sealed envelopes con taining a randomisation code were selected by the study pharmacist from either the male or female pile. The pharmacist was not involved in patient outcome assessment. All other study staff providing care or assessing outcomes, and the participants themselves, remained masked to the intervention group after assignment.
Procedures
We crushed 15 mg base primaquine phosphate tablets and dissolved them in 15 mL of drinking water to produce a stable 1 mg/mL solution. We drew up the assigned dose to the nearest 0•5 mL through a sterile syringe and immediately gave it to each participant in a plastic cup or spoon. We administered all treatments after the children had eaten a fatty snack (biscuits) and then directly observed the patients. If a child vomited within 30 min, treatment was re-administered. Those who vomited more than three times were excluded from the study and were treated for complicated malaria.
Enrolled participants were reviewed on days 0, 1, 2, 3, 7, 10, 14, 21, and 28, or on additional days if they presented at the clinic. We did systematic and prospective assessments for adverse events. We graded new or worsening symptoms, examination fi ndings, or laboratory abnormalities according to a severity scale (adapted from the WHO toxicity grading scale for determining the severity of adverse events and from the National Institutes of Health, Division of Microbiology and Infectious Diseases paediatric toxicity tables published in January, 2003) 23 and assessed causal associations with the study drug. We implemented a standardised protocol to detect episodes of haemolytic anaemia, which we have published elsewhere. 21 On scheduled visits, we collected roughly 500 μL of venous blood for laboratory assessments. On all visits, we did asexual malaria parasite counts, in which we enumerated parasites per 200 white blood cells; we read 100 microscopy fi elds in the Giemsastained thick blood fi lm before we judged a slide to be parasite negative. At enrolment, we read slides twice specifi cally for gametocytes, following the same procedure as that for asexual parasites. We measured haemoglobin con centration on days 0, 1, 2, 3, 7, 10, 14, 21, and 28 with self-calibrating HemoCue 201+ photometers (HemoCue; Angelholm, Sweden). We assessed gametocytaemia by quantitative real-time nucleic acid sequencebased analysis (QT-NASBA) with Pfs25 mRNA 24 on days 0, 2, 3, 7, 10, and 14. The timing of gametocytaemia measure ments was based on fi ndings from previous studies that suggested the gametocyte-clearing eff ect of primaquine is restricted to the fi rst 2 weeks after treatment. 7, 25 We extracted nucleic acids from 50 μL blood samples in L6 buff er (Severn Biotech Limited, Kidderminster, UK) with Total Nucleic Acid Isolation Kits-High Performance (Roche Applied Science, Mannheim, Germany) and a MagNA Pure LC automated extractor (Roche Applied Science). The sensitivity of this assay is related to the volume of blood sampled and is in the range of 0•02-0•1 gametocytes per μL for the samples collected. 24 The primary endpoint for effi cacy was the noninferiority of the mean duration of gametocyte carriage in the test doses compared with the reference group of 0•75 mg primaquine base per kg. Secondary endpoints were the point prevalence of gametocytes on days 7, 10, and 14 after treatment, gametocyte circulation time, and the area under the curve (AUC) of gametocyte density over time after primaquine administration. For treatment outcomes in each group, defi nitions of adequate clinical and parasitological response, early treatment failure, and late treatment failure were according to WHO Methods for Surveillance of Antimalarial Drug Effi cacy. 26 The primary safety endpoint was the superiority of the arithmetic mean maximum decrease in haemoglobin concentration from enrolment to day 28 of follow-up in the primaquine treatment groups compared with the placebo group. Secondary safety endpoints were the superiority assessment of the day of haemoglobin nadir, the maximum percentage decrease in haemoglobin, the percentage of participants with haemoglobin con centration lower than 50 g/L, requirement for blood transfusion, evidence of black urine, and the frequency of severe adverse events.
Statistical analysis
In our sample size calculation, we took into consideration the primary endpoints for both effi cacy and safety. To guide the effi cacy calculation, we used the QT-NASBAmeasured duration of gametocyte carriage in a Tanzanian study, which was reduced from a mean of 28•6 to 6•3 days (SD 6) when primaquine (0•75 mg/kg) was added to ACT alone. 25 Effi cacy analyses were done on an intention-totreat basis. To assess non-inferiority of the test groups to the reference group with 80% power at the two-tailed 5% signifi cance level, with allowance for 10% loss to followup and with use of a proposed clinically relevant noninferiority margin of 2•5 days, the target sample size for effi cacy was 120 participants per group. However, during the course of review by the trial data safety monitoring board, the target sample size was reduced to 460 participants (ie, 115 per group instead of 120) because of a lower than expected loss to follow-up. For the safety component of our analysis, the sample size calculation was based on the mean decrease in Hemocue-measured haemoglobin concentration on day 7 after treatment with primaquine of 6 g/L (SD 15) in a previous Tanzanian study. 18 A sample size of 99 participants per group would provide 80% power to detect a diff erence in mean maximum decrease in haemoglobin between treatment groups of 6 g/L at a signifi cance level of 5%.
Data were double entered and transferred into Stata (version 12.0) for analysis. We estimated duration of gametocyte carriage and gametocyte circulation time in children with gametocytaemia on day 2 (the day of primaquine dosing) with a straightforward deterministic compartmental mathematical model 25 that allows for the release of gametocytes from sequestration and incorporates baseline gametocyte densities into model estimates. The model allows the duration of gametocyte carriage to be estimated as a continuous outcome. As the spacing between sampling times increases, some uncertainty is expected, but this was judged to be acceptable for estimates during the fi rst 14 days after initiation of treatment. We compared treatment groups for non-inferiority to the reference group with two-sided 95% CIs. Because the distribution of gametocyte densities was expected to be skewed, all density analyses involved log10-transformed data and we used geometric means as summary statistics. We assessed the AUC of gametocyte density per participant with the linear trapezoid method 27 and log10-transformed the data. We used ANOVA to compare log AUC with the reference treatment group. We compared gametocyte point prevalence estimates per treatment group with the reference group with use of the prevalence ratio with 95% CIs. We adjusted all effi cacy analyses for gametocyte density at enrolment, and tested the potential eff ect of sex by adding this variable to multivariate models and by doing a stratifi ed analysis.
The primary safety outcome, maximum decrease in haemoglobin (g/L) during follow-up compared with the measurement at enrolment, is expressed as an arithmetic mean per treatment group and pairwise comparisons made between placebo and each of the primaquine groups, with unpaired t tests. We used a cutoff for signifi cance tests of p=0·05 for the superiority analysis. We compared the occurrence of adverse events between groups; the signifi cance level was adjusted for several comparisons by Bonferroni correction. This trial is registered with ClinicalTrials.gov, number NCT01365598.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study. All authors reviewed the report and agreed to submit for publication.
Results
We screened 1215 children with a history of fever and a positive blood smear at Walukuba Health Centre for eligibility to enrol in the study. The most frequent reason for exclusion was having taken antimalarial drugs in the previous 48 h (fi gure 1). Between December, 2011, and December, 2012, we enrolled and randomly allocated 468 children, 461 of whom completed treatment and contributed data for the assessment of safety and effi cacy (fi gure 1). 36 of these 461 children (8%) did not complete 28 day follow-up. The proportion lost to follow-up did not diff er signifi cantly between treatment groups, but was highest in the placebo group (fi gure 1). Baseline characteristics were similar in all treatment groups (table 1). 199 of 461 (43%) children were anaemic at baseline (haemoglobin concentration <110 g/L). Treatment failure, assessed clinically and microscopically, was rare (table 2) and did not diff er signifi cantly between groups (p=0•68).
Gametocyte prevalence at enrolment was 22•6% (104/461) by microscopy and 81•8% (365/446) by QT-NASBA (table 1) , and did not diff er between treatment groups (p=0•91 for microscopy and p=0•42 for QT-NASBA). Gametocyte density at enrolment was numerically higher in the 0•75 mg/kg reference group (table 1) Figure 1 : Trial profi le AL was given as six doses over 3 days (days 0, 1, and 2); PQ or placebo was given together with the fi fth dose of AL on the morning of day 2. The two post-treatment exclusions in the 0·4 mg/kg treament group (because of delayed confi rmation of parasitaemia) were followed up for safety. G6PD=glucose-6-phosphate dehydrogenase. AL=artemether-lumefantrine. PQ=primaquine. ITT=intention to treat. Haemoglobin concentration (g/L) 113 (15) 109 (15) 112 (15) 112 (14) Geometric mean sexual parasite density, parasites/mL (IQR) 
Data are % (n/N), median (IQR), or mean (SD), unless otherwise indicated. QT-NASBA=quantitative real-time nucleic acid sequence-based analysis. Data are mean (95% CI) or n/N (%). Except for the duration of gametocyte carriage, all estimates were adjusted for gametocyte density at enrolment. *p values are for comparison with reference 0·75 mg/kg treatment group. †Calculated for all children who had gametocytes on the day of primaquine or placebo administration. (table 3) . We recorded no diff erence in prevalence between the 0•4 mg/kg group and the reference group throughout follow-up (table 3, The timing of the nadir in haemoglobin was independent of treatment group, and the greatest contribution to the total decrease in haemoglobin occurred before day 2 when the study drug was administered. By day 28, in all treatment groups, haemoglobin concentrations had recovered and exceeded baseline concentrations (fi gure 4). We recorded no cases of black water fever; red, black, or tea-coloured urine; or severe haemolysis; and no child needed a blood transfusion. Sex had no eff ect on safety outcomes (data not shown).
The proportion of participants having adverse events did not diff er between treatment groups after adjustment of signifi cance levels for multiple comparisons (data not shown). In the sex-stratifi ed analysis, the maximum reduction in haemoglobin concentration seemed to be larger in the 0·75 mg/kg group compared with the placebo group in girls (p=0·023), but this diff erence was not statistically signifi cant after correction for multiple comparisons (Bonferroni threshold level for signifi cance p=0·0083). One child, aged 1·5 years, had a haemoglobin concentration of less than 50 g/L, which was the only severe adverse event. This boy, who received 0•4 mg/kg primaquine, had a baseline haemoglobin concentration of 99 g/L. On day 9 of follow-up, he underwent an elective surgical procedure in a mobile clinic. The mother reported no attempt at haemostasis postoperatively and the child had bled severely. By day 14, his haemoglobin concentration had fallen to 49 g/L without clinical compromise. After wound care and treatment with iron and folate, his haemoglobin concentration recovered to 106 g/L on day 28. This event was judged to be unrelated to the study drug.
Discussion
This study is the fi rst formal dose-fi nding trial to assess P falciparum gametocyte clearance after treatment with single-dose primaquine when given in combination with an ACT (panel). We showed that the duration of gametocyte carriage was roughly halved when 0•75 mg primaquine per kg was given in addition to ACTs. A reduced dose of 0•4 mg/kg had a non-inferior gametocytocidal eff ect compared with the WHO reference dose, whereas the duration of gametocyte carriage was inconclusive for non-inferiority in the 0•1 mg/kg group and gametocyte prevalence was higher during follow-up than at baseline. Safety outcomes did not diff er signifi cantly between the treatment groups.
In this population of children with uncomplicated clinical malaria, gametocytes were detected at baseline in a quarter of children by microscopy compared with fourfi fths by molecular methods, which is consistent with previous fi ndings and emphasises the inadequate sensitivity of microscopy in identifi cation of potentially infectious people. 31 Gametocyte prevalence decreased during follow-up; roughly half of the patients with gametocytes at enrolment cleared their gametocytes during the fi rst 2 days of treatment, before primaquine was given. These dynamics diff er from those reported in children in a previous ACT-primaquine trial that showed a more gradual reduction in gametocyte prevalence after ACT, 7 but are similar to those recorded in symptomatic Kenyan children of the same age group. 3 Although primaquine shortened the duration of gametocyte carriage, we noted that even the highest single dose of the drug did not render all participants gametocyte negative. In previous studies in Burma and Indonesia, microscopic gametocytes persisted in a few individuals 21 days after primaquine treatment. 8, 9 In our study, six of 106 (5·7%) children were gametocyte positive by molecular methods on day 14 after initiation of treatment, even with the highest dose of primaquine. However, the density of these persistent gametocytes was much lower than that at enrolment. We used gametocyte density estimates for secondary outcome measures because no clear lower threshold gametocyte density that is needed for successful mosquito infection has been established. [32] [33] [34] The gametocyte circulation time, which was calculated on the basis of the rate of decrease of gametocyte densities after treatment, was signifi cantly longer in the placebo and 0•1 mg/kg groups than in the reference group, but did not diff er signifi cantly between the 0•4 mg/kg group and the reference 0•75 mg/kg group. The AUC of gametocyte density over time, a summary measure for malaria transmission potential, 7, 27, 35 was numerically higher in the placebo group and 0•1 mg/kg dose group than in the 0•75 mg/kg dose group, but this diff erence was statistically signifi cant only for the 0•1 mg/kg dose group. There was no siginfi cant diff erence in the AUC between the 0•4 mg/kg and the 0•75 mg/kg dose groups. Baseline diff erences in asexual parasites between treatment groups did not result in diff erences in baseline gametocyte prevalence or density or diff erences in treatment outcome, and did not confound the comparison of gametocyte dynamics between groups.
Although we used sensitive molecular gametocyte detection methods in our trial and therefore provide detail that is absent from most other primaquine trials, a relevant shortcoming of this and other studies is that gametocyte infectiousness to mosquitoes was not established. A proportion of the gametocytes that are observed by microscopy shortly after primaquine treatment might be non-infectious. 15 Whether or not Pfs25 mRNA can be detected from non-viable gametocytes is unknown, and a proportion of the gametocytes that we detected could have been non-infectious. We might, therefore, have underestimated the transmission-blocking eff ect of primaquine. None of the available gametocyte detection devices allow inferences to be made about the infectiousness of gametocytes to mosquitoes, and only mosquito feeding assays can provide defi nitive evidence for the transmissibility of gametocytes. However, limitations do exist in the extent to which labour-intensive mosquito feeding assays can be used in clinical trials. 36 Although gametocyte measurements can be done repeatedly from the same patient, the few clinical trials that have used mosquito feeding assays typically do feeding experiments at one timepoint per participant 3, 37, 38 and thereby ignore the dynamics of gametocyte infectivity. 38 Future studies that investigate the gametocytocidal eff ects of low-dose primaquine should therefore preferentially include mosquito feeding assays at intervals during follow-up.
A further limitation of this study was the absence of available paediatric dose formulations for primaquine, which necessitated titration of crushed primaquine in solution for accurate dosing. Although crushed tablets have been used previously for the 0•75 mg/kg dose, 7, 8 this approach might have aff ected effi cacy, especially of the lowest dose (0•1 mg/kg). More data for the relative bioavailability of diff erent formulations of primaquine are needed. Hence, a prerequisite to the scaling up of primaquine deployment will be the availability of reliable paediatric formulations for low doses of the drug.
This study aimed to establish the effi cacy and safety of low-dose primaquine in people with normal G6PD enzyme function. G6PD-defi cient children were excluded from this study based on the fl uorescent spot test, the most widely used enzyme function test 13 that detects enzyme function to a cutoff of about 20-30% of normal activity. 39 We decided to exclude G6PD-defi cient children so that we could fi rst establish the lowest effi cacious dose before vulnerable patients are exposed to a potentially haemolytic drug. Although haemolysis has been reported in people without common mutations in the G6PD enzyme, 29 the exclusion of those with abnormal enzyme function does clearly limit the generalisability of the safety outcomes of this study and this issue needs to be addressed in future studies. Given this caveat, haemoglobin concentrations fell most rapidly in the fi rst 2 days after enrolment in all study groups, which implies that the greatest eff ect on haemoglobin was caused by clinical malaria rather than a drug eff ect. Thereafter, haemoglobin recovered to premorbid concentrations. A similar trend has been recorded in children in Tanzania, 7 and in populations in Burma 30 and Indonesia. 9 We recorded no children with objective measures of clinically signifi cant haemolysis or black urine, or who needed hospital admission or blood transfusion. The only severe adverse event was in a child who underwent an elective surgical procedure unrelated to the clinical malaria episode on day 9 and therefore after the expected duration of primaquineassociated haemolysis.
In this dose-fi nding trial, primaquine administration was delayed until day 2 after initiation of schizonticidal therapy. This timepoint is when, in the context of uncomplicated malaria, the rate of malaria-attributable haemolysis is expected to be falling, and comparisons of haematological eff ects between dose groups are expected to be less aff ected by the consequences of acute malaria infection. In operational terms, administration of primaquine on the fi rst day of schizonticidal treatment is probably advantageous, and comparisons of the effi cacy of day 0 versus day 2 administration will be important.
For more than 40 years, WHO has recommended a single dose of 0•75 mg primaquine base per kg in 
Systematic review
We searched PubMed on May 25, 2013, without date or language restrictions, with the terms "primaquine" and "malaria, falciparum" and "gametocyte" or "primaquine" and "malaria, falciparum" and "transmission". We identifi ed no randomised controlled trials assessing the dose-response relation of primaquine for gametocytocidal activity. A Cochrane review of the transmission-reducing effi cacy of primaquine published in September, 2012, identifi ed fi ve trials assessing a primaquine-artemisinin combination therapy combination that satisfi ed the criteria for inclusion and none of these analysed a range of doses. 28 Three studies have assessed the haematological safety of primaquine with artemisinin combination therapies, 7, 29, 30 but our trial is unique in that it was specifi cally powered to assess safety outcomes. A search of clinical trial registration sites for primaquine dose-fi nding trials for transmission blocking showed one trial that is underway in The Gambia (NCT01838902) to assess the effi cacy of artemisinin combination therapy alone, and with 0·2 mg/kg, 0·4 mg/kg, or 0·75 mg/kg primaquine base in asymptomatic patients. This trial is scheduled for completion in 2015. Another study (NCT01743820), which is in development, will assess primaquine dose escalation from 0·125 mg/kg in 50 participants randomly allocated to diff erent dosing groups. Several other registered studies with primaquine for Plasmodium falciparum do not involve dose-fi nding but will address relevant questions for the future wide-scale deployment of primaquine. These studies include a trial of the optimum timing of primaquine administration (NCT01906788, recruiting), primaquine pharmacokinetics (NCT01552330 and NCT01525511, both completed August, 2013), and a trial with mosquito feeding as an endpoint that will compare artemisinin combination therapy alone with 0·75 mg/kg primaquine (NCT01849640, not yet recruiting, with a scheduled 3-year timeline).
Interpretation
This study is, to our knowledge, the fi rst randomised, placebo-controlled trial to assess the dose-response relation of one dose of primaquine for gametocyte clearance and for safety in falciparum malaria. This trial was undertaken in African children with clinical malaria and normal glucose-6-phosphate dehydrogenase enzyme function. A dose reduction to 0·4 mg/kg primaquine base had demonstrable non-inferiority to the reference 0·75 mg/kg dose, whereas a dose of 0·1 mg/kg was inconclusive for non-inferiority. This trial was designed and started before a revision of the WHO guidelines recommending 0·25 mg/kg primaquine for transmission blocking, in light of which this new dose must now be assessed. In this population, all doses of primaquine had similar safety profi les to placebo. An study of low-dose primaquine in people with glucose-6-phosphate dehydrogenase defi ciency is warranted.
combination with schizonticidal drugs to reduce transmission of malaria. 40 However, no dose-fi nding trials underpinned this recommendation. The small evidence base for primaquine use has prompted uncertainty as to the benefi t of an intervention that carries a documented risk of haemolysis in malaria-endemic populations. 28, 41 The real threat of spreading artemisinin resistance 42 has led to urgency in addressing this problem. In September, 2012, while our study was ongoing, an evidence review group commissioned by WHO revised its recommended dose to 0•25 mg primaquine base per kg to be added to ACT to treat parasitologically confi rmed falciparum malaria infection in new programmes for malaria elimination and to stop the spread of artemisinin resistance. 43 This dose revision was based on underpowered historical studies, and the need for contemporary data was emphasised. 44 The 0•25 mg/kg dose was not assessed in our study, which is a limitation and leaves important questions to be addressed in future dose-fi nding trials. However, we have shown that gametocytocidal effi cacy is retained when the primaquine dose is reduced from 0•75 mg/kg to 0•4 mg/kg and that a dose-response relation exists for lower doses. The fi nding of reduced gametocytocidal effi cacy at doses lower than 0•4 mg/kg seems to contradict suggestions of uniform effi cacy in the range of 0•065-0•75 mg primaquine per kg. 16 This new information provides a valuable starting point for identifi cation of the most effi cacious and safest low dose of primaquine for transmission blocking. Subsequent investigations of primaquine should include assess ments of the effi cacy of doses lower than 0•4 mg/kg (including the newly recommended 0•25 mg/kg dose), with use of mosquito transmission endpoints to allow for diff erences in infectiousness of gametocytes persisting after treatment; the optimum timing of primaquine in combination with ACT; the pharmacokinetics of low-dose primaquine; and the safety of low-dose primaquine in people with G6PD enzyme defi ciency, which is of high priority. Because of diff erences in gametocyte dynamics between African and Asian settings 45 and diff erences in the severity of G6PD defi ciency across regions, 46 studies in a range of malaria-endemic settings are needed.
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